- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
The Burden of ASCVD and Evidence-Based Guidelines
Ian Riddock, MD, discusses the burden of atherosclerotic cardiovascular disease (ASCVD) and multi-societal guideline recommendations for lipid management.
EP: 1.The Burden of ASCVD and Evidence-Based Guidelines
EP: 2.A Patient’s Post-MI Journey
EP: 3.Improving the Care Continuum
EP: 4.Residual Cardiovascular Risk
EP: 5.Who is an Ideal Patient for Early Intensive Lipid Lowering?
EP: 6.Finding the Optimal Statin Dose
EP: 7.Therapy Beyond Statins in the Inpatient Setting
EP: 8.Using Adjunct Therapies in LDL Management
EP: 9.Ensuring Continuity of Care for the ASCVD Patient
EP: 10.Unmet Needs in Lipid Management
EP: 11.Defining “Optimal Care” for ASCVD Within Health Systems
EP: 12.What Does a Multidisciplinary Team Look Like?
EP: 13.The Future of LDL Management for Patients With High-Risk ASCVD
EP: 14.Enhancing Patient Care Through Guideline Adherence
EP: 15.Improving Access to PCSK9 Inhibitors in the Inpatient Setting
EP: 16.Appropriate ASCVD Treatment Outside of Closed Health Systems
EP: 17.Utilizing Quality Metrics in ASCVD
EP: 18.Improving Patient and Provider Engagement
EP: 19.Treatment Disparities in the Management of ASCVD
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
